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Rats with nephrotic syndrome (NS) have a fivefold increase
in lipids and a similar decrease in triglyceride-rich
lipoprotein (TRL) clearance. Lipoprotein lipase (LPL) is
reduced both in NS and in the Nagase analbuminemic rat.
These rats have nearly normal triglyceride levels and TRL
clearance, suggesting that reduction in LPL alone is
insufficient to cause increased TRL levels. Apolipoprotein E
(apoE) was decreased in lipoprotein fractions in NS, but not
in analbuminemia. Here we tested whether decreased apoE
binding to lipoproteins in NS contributes to hyperlipidemia
by decreasing their affinity for lipoprotein receptors. Plasma
apoE was increased 60% in both NS and analbuminemia
compared with control (CTRL) as a result of a 60% decreased
apoE clearance. Very-low-density lipoprotein and high-
density lipoprotein in NS had significantly less apoE per
mole of phospholipid compared with analbuminemia or
CTRL and significantly greater lipid content; however, apoE
binding did not differ by lipoprotein class or group. There
was a significant reduction of receptors for lipoproteins in
nearly all tissues in NS compared with CTRL and
analbuminemia. Thus, apoE within lipoprotein fractions was
reduced by dilution resulting from expansion of the lipid
fraction due to decreased lipolysis and not to differing
affinity for apoE. Decreased lipoprotein receptors result from
proteinuria and contribute to hyperlipidemia in NS.
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The nephrotic syndrome (NS) is a consequence of urinary
protein loss and is characterized by hypoalbuminemia and
increased blood lipid levels. Increased levels of triglyceride-
rich lipoproteins (TRLs) consisting of very-low-density
lipoprotein (VLDL) and intermediate-density lipoprotein
results almost entirely from decreased clearance.1,2 One initial
step in clearance involves engagement with lipoprotein
lipase (LPL) tethered to vascular endothelial cells that is
decreased as a consequence of decreased serum albumin
levels, which result from urinary protein loss in NS,3 but is
due to a defect in albumin gene expression in the Nagase
analbuminemic rat (NAR), with hereditary analbuminemia,
and thus occurs in the absence of proteinuria.4 Endothelial-
bound LPL is thus reduced to a greater extent in NAR than in
NS,5 yet clearance of both chylomicrons and VLDL are
normal or nearly so in these animals, and triglyceride
(TG) levels are only marginally increased,6 suggesting
that a defect, beyond LPL depletion, resulting in some
undefined way from proteinuria, contributes to defective
lipoprotein clearance in proteinuric organisms. The structure
of both high-density lipoprotein (HDL) and VLDL in NS
differs from that observed both in controls (CTRL) and
NAR. The primary structural difference we reported was that
VLDL and HDL from NS was depleted of apolipoprotein
E (apoE), whereas both HDL and VLDL from the NAR were
enriched in apoE.6–8
ApoE engages LPL allowing for more effective binding of
these proteins with the enzyme that initiates lipolysis, and
addition of apoE to VLDL obtained from nephrotic animals
increased lipolysis in vitro.6,7 We thus hypothesized that protei-
nuria altered the affinity for HDL and VLDL; decreased apoE
binding to lipoproteins in NS may contribute to hyperlipide-
mia by decreasing its affinity for lipoprotein receptors.
Lipoprotein receptors have an important role in the
clearance of TRLs and tissue uptake.9–14 Multiple receptors
mediate clearance of TRLs; the low-density lipoprotein
receptor (LDLR) binds to apoB and apoE, while VLDL
receptor (VLDLR) and the low-density lipoprotein recep-
tor–related protein (LRP) bind apoE. In addition to their
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different binding ligands, LDLR, VLDLR, and LRP have
different tissue distributions.15 LDLR and LRP are mainly
found in the liver, and VLDLR is primarily expressed in the
heart, skeletal muscles, adipose tissue, and brain. LDLR and
VLDLR have been shown to be decreased in muscle and heart
in nephrotic rats;16–18 however, it is unknown as to what the
tissue distribution of these receptors is in the NAR. Recent
studies have also shown that glycosylphosphatidylinositol
anchored HDL-binding protein 1 (GPIHBP1), an endothelial
cell-surface glycoprotein that binds LPL and is required for
the lipolysis of TRLs.19–21 It is unknown whether GPIHBP1 is
altered in NS and NAR, a defect that could amplify or efface
the effect of LPL depletion characteristic of hypoalbuminemic
states.
We conducted this study for three purposes: (1) to
establish the determinants of apoE levels in NS rats and NAR
in comparison with CTRL; (2) to establish the redistribution
of apoE within the lipoprotein fractions resulted from altered
affinity of apoE for different lipoprotein fractions in the
different models; and (3) to establish whether protein and
receptor density might be altered differently in NS and NAR
affecting tissue lipoprotein uptake and distinguishing the
effects of hypoalbuminemia in the presence and absence of
proteinuria.
RESULTS
Measurement of distribution of apoE, composition, and
particle size in lipoprotein fractions
The plasma concentration of apoE was significantly
greater in both NAR and NS compared with CTRL, but did
not differ between NAR and NS (Table 1). Plasma TG,
cholesterol, and phospholipids (PLs) were all significantly
greater (Po0.05) in NS than in NAR and CTRL (Table 1).
However, plasma TG and cholesterol concentrations in
the NAR were slightly but significantly greater (Po0.05)
than CTRL.
Characterization of lipoprotein composition. In all three
lipoprotein classes, the ApoE/PL ratio was greater in the
lipoprotein fraction from CTRL and lowest in the lipopro-
teins from NS. By contrast, lipid content was lowest in CTRL.
Cholesterol content of lipoprotein fractions from CTRL was
significantly lower and was greatest in NS (Table 2). Similarly,
TG content was greatest in VLDL and low-density lipopro-
tein (LDL) from NS, intermediate in the NAR, and also
lowest in CTRL. Thus, lipoproteins from NS were depleted of
apoE and enriched in core lipids (cholesterol and TG) per
mole of PLs, representing a measure of available lipoprotein
surface area (Table 2). ApoE/PL ratio in VLDL was over 15-
fold lower in NS than in CTRL, and over 3-fold lower in the
NAR (Table 2). There was also a significant decrease of apoE/
PL ratio in HDL in NS than in CTRL and NAR. By contrast,
the apoB/PL and apoC/PL ratios were no different in any of
the lipoprotein classes between CTRL, NS, and NAR.
Lipoprotein size distribution. Particle diameter of VLDL
from plasma showed marked heterogeneity among the three
groups of rats. Plasma VLDL particles from both NS and
NAR were larger than CTRL (Figure 1a). There was no
significant difference in the size distribution of LDL particles
among the three groups (Figure 1b). HDL diameters in the
NARs were significantly (Po0.05) smaller than those of both
NS and CTRL (Figure 1c).
Table 1 | Representative concentrations of serum lipids and protein from the CTRL, Heymann nephritis (NS), and NAR rats
CTRL (5) NS (6) NAR (5)
TG (mg/dl) 21.54±3.70 117.93±26.02*w 61.14±11.00*
Chol (mg/dl) 101.94±5.68 328.35±43.45*w 202.25±7.65*
PL (mg/dl) 150.31±9.50 394.15±45.72*w 206.23±11.89*
ApoE (mg/dl) 8.98±0.40 14.44±1.01*w 19.20±1.10*
Serum albumin (g/dl) 3.82±0.10 1.13±0.16*w o0.02*
Urine albumin (mg/24 h/100g) 196.30±12.85
Abbreviations: apoE, apolipoprotein E; Chol, cholesterol; CTRL, control; NAR, Nagase analbuminemic rat; NS, nephrotic syndrome; PL, phospholipid; TG, triglyceride.
Values are presented as mean±s.e., for n values as given in the table. Analysis of variance was used to compare the data from three groups. *Significantly different (Po0.05)
versus the CTRL group; wsignificantly different (Po0.05) versus the NAR group.
Table 2 | Chemical composition of lipoproteins separated
from the plasma of CTRL, Heymann nephritis (NS), and NAR
rats
CTRL (5) NS (6) NAR (5)
Group (n) Ratio/PL
VLDL
TG/PL 5.80±2.38 11.33±1.58* 7.16±3.13
Chol/PL 0.55±0.23 1.75±0.32* 1.13±0.56
ApoE/PL* 0.296±0.02 0.016±0.003* 0.31±0.002
ApoB/PL 0.185±0.03 0.181±0.025
ApoC/PL 0.275±0.02 0.284±0.018
LDL
TG/PL 1.18±0.16 7.80±1.45* 2.99±1.57
Chol/PL 0.25±0.024 3.10±0.65* 1.43±0.37
ApoE/PL 0.108±0.007 0.087±0.003* 0.103±0.006
ApoB/PL 0.161±0.026 0.142±0.028
ApoC/PL 0.117±0.009 0.128±0.02
HDL
TG/PL 0.10±0.01 0.09±0.01w 0.14±0.01
Chol/PL 1.07±0.10 6.87±0.99*w 2.02±0.11
ApoE/PL 0.102±0.022 0.004±0.00*w 0.032±0.002*
ApoA/PL 0.743±0.06 0.887±0.05
ApoC/PL 0.464±0.035 0.28±0.02
Abbreviations: apo, apolipoprotein; Chol, cholesterol; CTRL, control; HDL, high-
density lipoproteins; LDL, low-density lipoproteins; NAR, Nagase Analbuminemic
Rat; NS, Nephrotic Syndrome; PL, phospholipid; TG, triglyceride; VLDL, very-low-
density lipoproteins.
Values are presented as mean±s.e., for n values as given in the table. Analysis
of variance was used to compare the data from three groups. *Significantly
different (Po0.05) versus the CTRL group; wSignificantly different (Po0.05) versus
the NAR group.
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ApoE clearance and absolute turnover rate in HN,
NAR, and CTRL
ApoE clearance was significantly greater in CTRL animals
(1.50±0.15ml/100 g body weight/h) than either NS (0.87
±0.15ml/100 g body weight/h) or NAR (0.94±0.12ml/100 g
body weight/hr) (Table 3). The difference in clearance between
NAR and NS was not significant. At steady state, the product
of apoE concentration and clearance is total apoE absolute
catabolic rate per unit time and is equal to apoE synthetic rate
at steady state. ApoE absolute catabolic rate was not different
among the experimental groups (Table 3). Thus, the difference
in plasma concentrations between the three groups was
entirely a consequence of differences in apoE clearance with
no difference in apoE synthetic rate.
Binding of apoE to lipoprotein fractions
The C-terminal region of apoE has been identified as the
protein’s principal lipid-binding domain.22–24 As shown
previously,25,26 a decrease in the self-association of lipid-free
apoE protein is observed via the decreased broadening of the
electron paramagnetic resonance (EPR) spectrum resulting
from a diminished magnetic coupling between spin labels
attached to position Trp264 in the C-terminal domain of the
protein. Upon lipid binding, the self-association of the C-
terminal domain is disrupted, resulting in larger EPR
amplitude due to the decreased dipolar broadening. A typical
response of the spin-labeled apoE4-W264C as a function of
VLDL is shown in Figure 2. The apoE4 isoform is chosen
because of the absence of additional cysteine moieties in
regions of the protein that do not engage in lipid binding,
thus interfering with the measurement of changes in the
region of interest. Each sample contains the identical amount
of spin-labeled apoE4; however, the lipid-free sample (black
trace) displays the maximum amount of spectral broadening.
The loss of broadening is dependent on the amount of
VLDL added, with VLDL at 0.64mg/ml PL (blue trace)
inducing a much greater change than does a lower concen-
tration of VLDL with the same concentration of label (red
trace).
With lipoprotein concentration serial dilution (log order),
we found that apoE bound to all particles in a saturable
manner. There was no significant difference in apoE binding to
VLDL, LDL, and HDL obtained from CTRL and NS (Table 4).
No significant difference in binding affinity was found either
by lipoprotein type (HDL, LDL, and VLDL), or between NS
and CTRL animals (Figure 3 and Table 4).
Measurement of tissue lipoprotein receptors and GPIHBP1
VLDL receptors expressed in the liver, heart, muscle, and
adipose tissue from NS were significantly decreased com-
pared with CTRL or NAR (Figure 4). There was a relative
abundance of VLDLR in the NAR compared with CTRL.
Hepatic LDLR was decreased in NS compared with CTRL
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Figure 1 |Dynamic light scattering–determined diameter
distribution of very-low-density lipoprotein (VLDL), low-
density lipoprotein (LDL), and high-density lipoprotein (HDL)
isolated from control (CTRL), nephrotic syndrome (NS), and
Nagase analbuminemic (NAR) plasma. (a) Percentile
distribution of plasma VLDL particle density function (area).
(b) Percentile distribution of plasma LDL particle density function
(area). (c) Percentile distribution of plasma HDL particle density
function (area).
Table 3 | ApoE concentration, clearance and FCR in NAR,
Heymann nephritis (NS), and CTRL animals
Group
ApoE concentration
(mg/dl)
ApoE clearance
(ml/100g)
ApoE catabolic
rate (mg/100g/day)
CTRL (7) 8.98±0.40 1.50±0.15 3.34±0.45
NS (7) 14.44±1.01* 0.87±0.15* 2.94±0.66
NAR (9) 19.20±1.10* 0.94±0.12* 4.24±0.43
Abbreviations: apoE, apolipoprotein E; CTRL, control; FCR, fractional catabolic rate;
NAR, Nagase analbuminemic rat; NS, nephrotic syndrome.
Values represent means±s.e., for n values as given in the table. Analysis of variance
was used to compare the data from three groups. *Significant difference from CTRL
(Po0.05).
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and NAR; however, this was not the case in the heart. There
was significantly less abundance of heart LDLR in the NAR
than in NS and CTRL. GPIHBP1 in red muscle was
significantly reduced in NS compared with both CTRL and
NAR, but no difference was observed between CTRL and
NAR. In contrast, this receptor in the heart was significantly
reduced in both NS and NAR. No significant difference of
hepatic LRP was found among groups.
DISCUSSION
The primary process that causes increased lipid levels,
especially TG levels, is decreased clearance.3,27 It has been
established that there is both depletion of LPL and abnormal
distribution of apoE in lipoprotein classes28,29 in NS;
however, LPL is also reduced in the NAR, and these animals
have limited increase in lipid levels. Clearance of TRL is
reduced by approximately an order of magnitude in NS and
is essentially normal in the NAR, explaining their nearly
normal levels of TRLs.3,16,25 In this study, we find that apoE
levels in plasma are increasedB60% in NS accompanied by a
reduction in apoE clearance ofB60%. By contrast, TG levels
are increased Bfivefold in NS compared with CTRL,
Figure 2 | Electron paramagnetic resonance (EPR) spectral
response of spin-labeled apolipoprotein E-4 (apoE4) upon
binding to rat plasma lipoproteins. Shown are the EPR spectra
of spin-labeled apoE4 in the absence and presence of isolated
very-low-density lipoprotein (VLDL). Each spectrum represents the
same number of spins from a final spin-labeled apoE4
concentration of 0.5mg/ml. The lipid-free protein (black trace)
displays the broadest spectrum. To demonstrate how the loss
of broadening relates to VLDL binding, two concentrations
(mg/ml of phospholipid) of VLDL were added: 0.026 (red line) and
0.64 (blue line).
Table 4 | Bmax and KD of apoE binding to lipoproteins from
CTRL and NS animals
Group Bmax KD
VLDL
CTRL (7) 140.30±18.38 0.0075±0.0045
NS (7) 211.6±21.56 0.0083±0.0042
LDL
CTRL(7) 148.00±3.36 0.0023±0.00029
NS (7) 119.90±10.98 0.01349±0.0055
HDL
CTRL (7) 151.7±7.45 0.0035±0.0009
NS (7) 140.00±16.7 0.0067±0.0039
Abbreviations: apoE, apolipoprotein E; CTRL, control; HDL, high-density lipoproteins;
LDL, low-density lipoproteins; NS, nephrotic syndrome; VLDL, very-low-density
lipoproteins.
Values represent means±s.e., for n values as given in the table. Analysis of variance
was used to compare the data from three groups.
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Figure 3 | Saturation curves of binding of spin-labeled apoE4
to lipoproteins isolated from control and nephrotic syndrome
(NS) rats. Spin-labeled apolipoprotein E-4 (apoE4) (final protein
concentration 0.5mg/ml) incubated with very-low-density
lipoprotein (VLDL), low-density lipoprotein (LDL), and high-
density lipoprotein (HDL) isolated from control and NS rats at
increased dose of phospholipid (PL) concentration overnight at
4 1C. The binding was measured by broadening of the electron
paramagnetic resonance spectrum of spin-labeled apoE by
increasing concentrations of lipoproteins. The curve was
estimated by nonlinear regression.
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suggesting that there is a mismatch in the relative defect in
apoE clearance and this mismatch affects the final distribu-
tion of apoE within the apoE and TRL, diluting apoE on the
surface, measured by PLs. There was no difference in apoE
affinity or maximum binding capacity of any of the
lipoproteins. The differences in apoE content of each
lipoprotein subclass were a consequence of apoE availability
and lipoprotein surface area available for binding. Although
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Figure 4 |Protein expression of low-density lipoprotein receptor (LDLR), very-low-density lipoprotein receptor (VLDLR), lipoprotein
receptor–related protein (LRP), and glycosylphosphatidylinositol-anchored high-density lipoprotein-binding protein 1 (GPIHBP1) in
the liver, heart, muscle, and adipose tissues of the control, nephrotic syndrome (NS), and Nagase analbuminemic rats (NARs). The
relative density of the liver, heart, muscle, and adipose LDLR (a), VLDLR (b), LRP (c), and GPIHBP1 (d) mass in NS and NA rats compared with
the controls. Representative western blot of the liver, heart, muscle, and adipose LDLR, VLDLR, LRP, and GPIHBP1 versus glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) from control, NS, and NARs. Tissue lysates were separated on 4–20% sodium dodecyl sulfate
polyacrylamide gel electrophoresis and immunoblotted with anti-GAPDH, anti-LDLR, anti-VLDLR, anti-LRP, and anti-GPIHBP1. Values
represent the mean±s.e.m. of six rats.
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apoE may serve as a ligand for lipoprotein receptors, the
observed difference in lipoprotein apoE levels is unlikely to be
the primary determinant for defective lipoprotein removal,
but instead likely results from greatly impaired clearance of
lipids relative to the reduction in clearance of apoE.
ApoE, an exchangeable component of TRL and HDL, has
a key role in TRL clearance and cholesterol homoeostasis.
ApoE modulates plasma and cellular cholesterol levels by its
ability to (1) act as a ligand for the LDL receptor family30 and
heparin sulfate proteoglycans,31 which leads to cellular
uptake and clearance of TRL remnant lipoprotein particles,
and (2) promote cholesterol efflux from peripheral tissues to
nascent HDL particles in atherosclerotic lesions.32 It is known
that TRLs are cleared via apoE-mediated clearance pathways
including receptor-dependent (e.g., LDLR, LRP, and VLDLR)
and receptor-independent pathways (heparin sulfate proteo-
glycans33,34 and the scavenger receptor class B type I.35–37 In
this study, we found that a 60% increase of apoE
concentration in NS was accompanied by a 60% reduction
in clearance without the difference of apoE turnover rate
among the NS, NAR, and CTRL groups. Our previous
study showed that apoE mRNA was not increased in either
NS or NAR,28 consistent with the current observation.
These studies suggested that the increase in plasma apoE
concentration in NS is a consequence of a reduced clearance
with no difference in apoE synthesis. The increased VLDL
particle size also indicated that the defect is in bulk particle
removal rather than lipolysis of particles per se, and thus
the increase in surface area is a consequence of more apoE-
poor particles.
There was no significant difference in lipoprotein binding
to apoE among the groups. Thus, altered apoE-binding
affinity is unlikely to be the cause of the observed apoE
distribution within lipoprotein classes in NS.
Several steps occur during TRL clearance. First, circulating
TRLs bind to LPL and other proteins that have a role in
lipoprotein clearance. Second, TRLs interact with LPL, which
hydrolyzes TG, and produce TRL remnants. Third, the liver
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Figure 4 | Continued.
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removes remnants via TRL apoE or apoB binding to
receptors. The primary difference between NS and both
NAR and CTRL is a significant reduction in the presence of
LDLR, VLDLR, and LRP in virtually all tissues except the
heart. Indeed, the VLDLR was significantly increased in the
NAR. These receptors may facilitate the removal of TRLs and
partially explain the near-normal removal of them in the
NAR despite decreased LPL. A recent study has shown that an
endothelial cell protein, GPIHBP1, is required for the
lipolysis of TRL via the binding to LPL.38,39 GPIHBP1 is
located within the lumen of capillaries of the heart, skeletal
muscle, and adipose tissue.38 In the current study, we
found that there was significantly lower expression of red
muscle GPIHBP1 in NS compared with the CTRL and NAR.
Heart GPIHBP1 in NS or NAR was significantly less than
that in CTRL, which is consistent with the lower expression
of LPL in NS and NAR. Heart GPIHBP1 was significantly
greater in NAR than NS. Our result is consistent with the
recent study from the Vaziri group40 that demonstrated
GPIHBP1 deficiency in skeletal muscle, adipose tissue, and
myocardium in rats with chronic kidney disease with
proteinuria.
ApoE acts as a receptor-binding ligand at the surface of
TRLs. The degree of exposure of apoE at the surface of TRLs
and its affinity for the receptor both determine the uptake
and catabolism of these lipoproteins. ApoE and/or apoB
contribute to the interaction of lipoproteins with several
cellular receptors. The degree of exposure of apoE at the
surface of normo- and hyperlipidemic VLDL can modulate
their uptake by the receptors. Normolipidemic VLDL is
poorly recognized by the LDLR, whereas hypertriglyceri-
demic VLDLs are cleared more efficiently through this
pathway. Our receptor data showed a significant reduction in
LDLR and VLDLR in NS tissues, which is consistent with the
previous study,41 whereas we found that receptors in the NAR
tissues were similar to the CTRL tissues, which may explain
the nearly normal clearance of TRL in the NAR, suggesting
that the principal differences observed in TRL clearance
between NS and CTRL are a consequence of reduction in
receptor density rather than affected by either LPL or apoE
concentration on lipoproteins.
The mechanism of hyperlipidemia in NS is a very
complicated process that involves many proteins, lipids,
and other structures, as well as multiple pathways. In
addition to the GPIHBP1, LPL, VLDLR, LDLR, and LRP,
hepatic TG lipase has a major role in clearance of TGs and
PLs in intermediate-density lipoprotein and HDL particles.
The Vaziri group has demonstrated a significant reduction of
hepatic TG lipase expression and activity in animals with
puromycin aminonucleoside-induced NS and Imai rats with
spontaneous glomerulosclerosis.42–44 The same group has
also demonstrated that downregulation of hepatic HDL
receptor, SRB1, in NS contributes to the associated
dyslipidemia and elevation of the lipid contents of HDL,
and that LCAT deficiency caused by its urinary losses in NS
contributes to alteration of the HDL structure.45,46
In summary, the apoE pool size is increased but diluted
within the lipoprotein classes by processes not related to
apoE binding, but possibly a consequence of a greater
quantitative defect in removal of lipids from lipoproteins
than of apoE. Reduced lipoprotein receptors and GPIHBP1
might contribute to the hyperlipidemia in NS, but the
mechanism by which proteinuria affects lipoprotein receptors
is unclear.
MATERIALS AND METHODS
All procedures involving animals were approved by the Animal
Review Committee at the University of California Davis and the
Department of Veterans Affairs.
Protocol 1: Measurement of distribution of apoE within
lipoprotein fractions, lipoprotein composition, and particle
size
Male Sprague–Dawley rats (150 g) were obtained from Simonson
Farms (Hayward, CA) for CTRL animals and for experiments in
which the NS was induced. The NARs were obtained from
our own breeding colony maintained at the University of
California Davis (Davis, CA) as described previously47 and are on
a Sprague–Dawley background. All animals were kept in
24-h light/dark rooms and fed Purina Purified Protein diet 5755
(LabDiet, St Louis, MO). These studies were conducted in five
CTRL, six NS, and five NARs. NS was induced by intraperitoneal
injection with sheep anti-FX1a serum to induce proteinuria.
The antibody was a gift from Dr William Couser (Seattle, WA).
Urinary albumin excretion was determined 2 weeks following
injection of FX1A, and rats with albuminuria of 4300mg/day
were selected. Blood was obtained from a tail vein following
an overnight fast to establish baseline lipid levels. Rats were
anesthetized with an intraperitoneal injection of 75mg/kg (CTRL)
or 40mg/kg (NS and NAR) sodium pentobarbital and were then
killed by aortic puncture and exsanguination to obtain blood for
lipoprotein purification.
Lipoprotein isolation and characterization. Lipoproteins were
subfractionated from ethylenediaminetetraacetic acid plasma ac-
cording to their hydrated density by sequential density-gradient
ultracentrifugation.48
Plasma lipids and lipoprotein composition analyses. TG
concentration was determined enzymatically (Sigma Chemical, St
Louis, MO). Total cholesterol and PL levels were measured using
enzymatic kits (WAKO, Richmond, VA).
Analysis of lipoprotein fraction particle size. VLDL diameters
were measured by dynamic laser light scattering (Microtrac series
250 ultrafine particle analyzer with a laser probe tip (UPA-250;
Microtrac, Clearwater, FL)) and the Microtrac software (Honeywell,
Washington, PA) as described in Wang et al.49–51 The results of
primary data collection can be expressed as a distribution of particle
area.52 Raw particle diameter distributions were converted to
population percentiles in order to facilitate statistical comparisons.
LDL and HDL particle size were measured using non-denaturing
gradient gel electrophoresis.53,54 Migration of lipoproteins in gel was
measured using an Odyssey imager and software (LI-COR, Lincoln,
NE). Calibration curves for LDL proteins were constructed by
plotting the logarithm of particle diameter against the distance
migrated relative to that of Rf (abscissa). Particle sizes were
calibrated by comparison with migration distances of standard
proteins of known diameter.55
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Enzyme-linked immunosorbent assay for ApoE. For measure-
ment of apoE in plasma and lipoprotein fractions, 100 ml
affinity-purified goat anti-rat apoE antibody (custom prepared)
prepared in 0.1M sodium bicarbonate was applied to 96-well
enzyme-linked immunosorbent assay plates (NUNC, Rochester,
NY) at a concentration of 20 mg/ml, with incubation at 4 1C
overnight. ApoE antibody and IgG HRP were obtained from Pierce
(Rockford, IL)
Protocol 2: Measurement of apoE fractional catabolic rate in
NS, NAR, and CTRL
ApoE clearance was measured in seven CTRL, seven NS, and nine
NARs.
Purification and radiolabeling of apoE. ApoE was isolated
from the density fraction d41.019 g/ml obtained by ultracentrifu-
gation from the plasma of female NAR.56 Purified apoE was
iodinated by a modification of the iodine monochloride method.56
125I-labeled apoE was reassociated with apoE-containing VLDL
particles. Sodium dodecyl sulfate polyacrylamide gel electrophoresis
followed by phosphor imaging was used to ensure that all 125I in
the lipoproteins prepared for clearance study was contained only
in apoE.
Measurement of apoE clearance. Blood was obtained after an
overnight fast from a tail vein immediately before apoE injection to
determine fasting TG, albumin, and apoE levels. A measure of 7 mg
of VLDL 125I-labeled with apoE, containing 1–2 107 c.p.m. of 125I,
was injected as a bolus into the tail vein. The animals were lightly
restrained but were not anesthetized. Blood samples of 150 ml
were obtained from a tail vein at 5, 15, 30, 60min, 2, 5, 10, 15, 22,
30, and 48 h following injection, and centrifuged to separate
plasma from red cells. Three 10-ml aliquots of plasma at each time
point were counted in a gamma counter (Perkin Elmer, Shelton,
CT) for 10min.
The plasma radioactivity disappearance curve was integrated by
the use of the numerical model using SAAM II (SAAM Institute,
Seattle, WA). Clearance is calculated as the dose injected/area under
the disappearance curve.56
Protocol 3: Measurement of binding of apoE in each
lipoprotein fraction
Animals. ApoE binding was measured in seven CTRL and
seven NS rats. The animal resources, housing, and diet were the
same as that in the protocol 1, except that animals were injected with
adriamycin (5mg/kg) (Adriamycin RDF: Pharmacia and Upjohn,
Milan, Italy) in tail veins to induce NS.
ApoE binding to lipoprotein fractions by EPR spectro-
scopy. We measured binding of apoE to each lipoprotein fraction
using spin-labeled apoE as a probe, to observe the protein’s structure
and dynamics by EPR spectroscopy. To generate the apoE probe, a
site-directed nitroxide spin label was introduced into the C-terminal
domain of human apoE4 as described by Hatters et al.
57 Briefly, the
gene encoding human apoE4 containing the W264-4Cys (apoE4-
W264C) mutation was expressed in Escherichia coli, purified, and
labeled with the thio-reactive MTS-SL spin label (1-oxyl-2,2,5,5-
tetramethyl-D3-pyrroline-3-methyl) methanethiosulfonate,58 a kind
gift from Prof. Kalman Hideg.
The spin-labeled apoE4 (264C) (0.75mg/ml protein in Tris-
buffered saline) was incubated overnight at 4 1C with a sample
containing saline, VLDL, LDL, or HDL. We performed a dose
response of apoE-binding affinity with constant spin-labeled apoE
(0.75mg/ml protein) and increasing amounts of experimental
lipoprotein at VLDL (PL: 0.0037, 0.0184, 0.092, 0.46, 2.3mg/ml),
LDL (PL: 0.07, 0.37, 1.84, 9.2 and 46mg/ml), or HDL (PL: 0.09, 0.45,
2.24, 11.2, and 56mg/ml). Samples were placed in quartz capillary
tube and scanned by EPR. EPR measurements were recorded in a
JEOL X-band spectrometer fit with a loop-gap resonator.59 Spectra of
samples were obtained by a 2-min scan over 400G at a power of
2mW and a modulation amplitude optimized to the natural line
width (1.5–2.5G) at room temperature as described.59,60 Data were
normalized according to the same spin number, as calculated from
the integrated intensities of the EPR spectra.
The concentration of the lipoprotein was increased over several
log orders in order to establish Bmax and the point of half saturation.
This experiment allowed us to establish both the binding
capacity and affinity of each protein for apoE. The concentration
of bound protein was calculated based on the measured spectrum.
The apparent dissociation constant (KD) and maximum binding
capacity (Bmax) were estimated by nonlinear regression using
the equation Y¼Bmax*X/(KDþX). Data were processed and
fitted using the GraphPad Prism software (GraphPad software,
San Diego, CA).
Protocol 4: Measurement of tissue lipoprotein receptors and
GPIHBP1
Tissue lipoprotein receptors were measured in six NS, six CTRL, and
six NARs. The animal resources, housing, and diet were described as
in protocol 1.
Tissue LDLR, VLDLR, LRP, and GPIHBP1 in rats were
quantified by western blot analysis. Rat tissue plasma membranes
were prepared according to the method of Vaziri et al.41 Protein
aliquots (50 mg) were detected by western blot analysis as described61
using primary antibodies: rabbit anti-GAPDH (1:5000) (Abcam,
Cambridge, MA), rabbit anti-LDLR (1:2000) (Abcam), rabbit anti-
LRP (1:3000) (Abcam), rabbit anti-GPIHBP1 (1:300) (Abcam), and
anti-VLDLR antibody (1:10) prepared according to Vaziri et al.41
Western blot analysis was carried out according to standard
protocols.61.
Statistical analysis. Values were expressed as mean±s.e. unless
otherwise noted. Difference between experimental groups was
determined by one-way analysis of variance. Po0.05 was considered
statistically significant.
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